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Drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity
syndrome (DIHS) involves a unique and severe adverse drug reaction. Patients present with fever, rash,
lymphadenopathy, hematological abnormalities, systemic illness, and may suffer from prolonged cour-
ses. Although the precise pathogenesis of DRESS/DIHS is not fully understood, it is widely considered to
be an immunological reaction to a drug or drug metabolites. In this review article, we discuss the his-
torical aspects of nosology, variable clinical and histopathological features, advantages and disadvantages
of using an international Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) and Japanese DIHS
criteria, pathogenesis, treatment, and long-term sequelae of DRESS/DIHS. Early recognition of this syn-
drome, withdrawal of suspected culprit drugs, and adequate supportive care are mainstays of improving
patient prognosis and reducing morbidities and mortality. Moreover, some DRESS/DIHS patients may
develop long-term sequelae, especially autoimmune diseases and end organ failure. Physicians should be
aware of these possibilities in patients after DRESS/DIHS and cautiously follow-up symptoms and lab-
oratory tests for early detection of these sequelae.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Adverse reactions to drug therapies are a concern for all medical
personnel and also for the general public. Drug complications are
the most common type of adverse event during hospitalization1
and the skin is one of the organs most often affected. According
to the literature, cutaneous adverse drug reactions affect 2e3% of
hospitalized patients.2,3 Fortunately, most of these reactions pre-
sent as benign maculopapular exanthema or urticaria.3 However,
severe cutaneous adverse reactions (SCARs) affect about 1 of every
1000 inpatients.4
SCARs to drugs are groups of idiosyncratic hypersensitivity re-
actions with a heterogeneous clinical presentation.5 Two of the
most notorious SCARs are StevenseJohnson syndrome (SJS) and
toxic epidermal necrolysis (TEN) due to their rapid progression and
high morbidity/mortality rates. With extensive reporting and bet-
ter education of physicians and patients, the incidence of both hasy, National Taiwan University
icine, Number 7, Chung-Shan
iwanese Dermatological Associatiogradually decreased. Recently, another SCAR has begun to attract
attention due to its unique clinical features and unknown patho-
genesis: drug reaction with eosinophilia and systemic symptoms
(DRESS); its description reﬂects the typical presentation of rash,
hematologic abnormalities, and systemic illness.
This peculiar syndrome was ﬁrst reported in the literature in
1937, where it was described as exfoliative dermatitis following
administration of sulfanilamide.6 Until 1950, systemic complica-
tions of this drug hypersensitivity, such as lymphadenopathy and
visceral involvement, had been widely reported.7 After this, an
increasing number of patients presenting with similar but variable
manifestations received diagnoses deﬁned by the drugs that caused
the reaction, including phenytoin hypersensitivity,8 dapsone hy-
persensitivity (sulfone syndrome),9 allopurinol hypersensitivity
syndrome,10 and anticonvulsant hypersensitivity syndrome.11
Because lymphadenopathy was commonly reported in these pa-
tients, the term “drug-induced pseudolymphoma” was once
confusedly used to describe such condition12 but then was super-
seded by “drug-induced hypersensitivity syndrome” (DIHS) to
differentiate its acute systemic symptoms from pseudolym-
phoma.13 These systemic hypersensitivity syndromes were
renamed as “drug rash with eosinophilia and systemic symptoms”n. Published by Elsevier Taiwan LLC. All rights reserved.
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tion of cutaneous involvement.
Even now, the underlying mechanisms of DRESS/DIHS are only
partially understood and many issues about this controversial en-
tity are still being debated. In this article, we will re-examine this
severe drug eruption and add new information to help clarify some
unrevealed topics about DRESS/DIHS.
Clinical presentation and pathological ﬁndings
Clinical symptoms and laboratory ﬁndings
DRESS/DIHS symptoms typically occur 2e6 weeks14 after drug
intake; however, reactions may not develop until 3 months later,
especially when the syndrome is induced by allopurinol.15 A high,
spiking fever (usually >38C) and rash are usually the ﬁrst signs,
and these are followed by other systemic reactions such as cervical,
axillary and inguinal lymphadenopathy, arthritis, or general mal-
aise. The rash begins as a nonspeciﬁc morbilliform eruption
(Figure 1A), which is indistinguishable from other less severe drug
reactions, but can progress to a generalized form or even to
erythroderma (Figure 1B). Facial and acral edema with periorbital
accentuation is an evocative sign for the diagnosis (Figure 1C) and
may induce blister formation due to severe dermal edema.14 The
cutaneous eruption later becomes conﬂuent and inﬁltrated
(Figure 1D) with purpuric changes, especially when it affects the
lower extremities (Figure 1E). As the rash resolves, the end stage
involves large sheet desquamation (Figure 1F). Occasionally,
pinhead-sized pustules (Figure 1G) and atypical target lesions
(Figure 1H) may also be observed. Mucosal regions can be involved
in DRESS/DIHS but in such cases, the symptom is usually mild, and
seen as cheilitis (Figure 1I) or erythematous pharynx rather than as
extensive erosions seen in SJS/TEN.16,17
Multiple organ involvement is another distinct feature of
DRESS/DIHS but the actual incidence varies. The liver and kidney
are the two most frequently involved organs, and the incidence
ranges from 50% to 87% and 10% to 53%, respectively.4,18,19 Anicteric
hepatitis presenting as elevated serum alanine aminotransferase is
more common in patients with DRESS/DIHS, but when it becomes
icteric, this usually signals a poorer prognosis.20 Most patients
recover from hepatitis without speciﬁc targeted management, but
acute liver failure may develop and can contribute to patient
mortality if liver transplantation is unsuccessful. In addition,
recurrent elevation of liver enzymes, with or without relapsing
fever and rash, may correlate with reactivation of human herpes-
virus 6 (HHV-6).21
Renal involvement usually presents with increased serum
creatinine levels and new-onset proteinuria. In our previous study,
chronic renal insufﬁciency and allopurinol-induced DRESS/DIHS
increased the risk of renal involvement.15 In addition, interstitial
nephritis, rather than tubular necrosis, was the more common
cause of acute renal failure in DRESS/DIHS patients. The severity of
renal dysfunction varies from a mild increase in serum creatinine
levels to the development of end-stage renal disease.
Although the incidence is lower, other visceral organs can be
involved during DRESS/DIHS. Pulmonary involvement presents as
nonproductive cough or breathlessness, which may be complicated
by acute interstitial pneumonitis, pleuritis, or adult respiratory
distress syndrome.22 Cardiac and muscular complications include
myocarditis,23 rhabdomyolysis,24 and atrioventricular block.25 The
diagnosis of DRESS/DIHS-induced myocarditis usually depends on
clinical symptoms (chest pain, unexplained tachycardia, hypoten-
sion), electrocardiogram changes (diffuse ST-T changes), and some
nonspeciﬁc changes on echocardiograms (reduction in ejection
fraction) and chest radiographs (cardiomegaly, pleural effusion).22Although the cardiac complications are rare, these can easily lead
to death. Thus, physicians should be alert for such clinical
symptoms.
Neurologic symptoms, such as headache, seizure, coma, or
disturbed speech are all usually reported, as signs of meningitis and
encephalitis. Hippocampal involvement points to a diagnosis of
limbic encephalitis and syndrome of inappropriate secretion of
antidiuretic hormone has been reported in DRESS/DIHS patients.26
HHV-6 encephalitis associated with drug hypersensitivity syn-
drome has been described but not necessarily always detected.27
Hypersensitivity syndrome may also results in acute pancrea-
titis,28 arthritis,29 or gastrointestinal bleeding.30 The severity of
organ involvement can vary from subclinical to fatal or can only be
recognized months or years later after the development of such
organ failures.17
Various hematologic abnormalities have been described in pa-
tients with DRESS/DIHS. Atypical lymphocytes and/or eosinophilia
is the most prominent and characteristic sign22; in our previous
study, the incidence was 63% and 52%, respectively.15 Other ab-
normalities include leukocytosis or leukopenia, thrombocytopenia,
and hypogammaglobulinemia in the early stages.31 Most hemato-
logic changes return to normal without causing signiﬁcant
morbidity. However, the presence of pancytopenia is signiﬁcant
because it predicts a poor prognosis,15 and hemophagocytic syn-
drome developing during the course of DRESS/DIHS may be an
underlying cause that is easily overlooked.
Pathological ﬁndings
No single pathological ﬁnding is speciﬁc enough to make a diag-
nosis of DRESS/DIHS; however, the results of skin biopsy will help
rule out other diseases, such as lymphoma or hematological and
infectious disorders.32 In most cases, diffuse or superﬁcial peri-
vascular lymphocytic inﬁltration is the most frequently observed
feature on dermatopathological slides. One or more reactive pat-
terns may accompany this inﬂammatory background, including
epidermal spongiosis (Figure 2A), basal cell vacuolization with the
presence of some dyskeratotic cells (Figure 2B and C), and promi-
nent endothelium (Figure 2D), possibly with red blood cell
extravasation.33 Eosinophils and dermal edemamay also be present
(Figure 2E). Severe perivascular lymphocytic inﬁltration may be
accompanied by endothelial damage and, in rare cases, by red blood
cell extravasation presenting as lymphocytic vasculitis (Figure 2F).
Earlier reports pointed to a band-like inﬁltrate of atypical lym-
phocytes with epidermotropism observed on the skin biopsy.14
However, we believe that the presence of atypical lymphocytes is
not a prominent feature, so that DRESS/DIHS can be differentiated
from lymphoma and pseudolymphoma. Moreover, recent serial
case studies have established that interface dermatitis with either a
vacuolar or lichenoid pattern indicative of basal cell degeneration is
another common feature of this severe drug reaction.15,19
Unique presentation of DRESS in Taiwan
The clinical manifestation of DRESS/DIHS is heterogeneous. Study
series conducted in different geographic areas also display some
individual and unique features, possibly reﬂecting the difference in
ethnicity or in medical care systems (Table 1).15,18,21,33 In Taiwan,
the most common cause can be traced to allopurinol. This ﬁnding
may be associated with higher prevalence of HLA-B*5801 in Han
Chinese and more prescription of allopurinol for asymptomatic
hyperuricemia in Taiwan. In addition, the prevalence of end-stage
renal disease in Taiwan ranked second in the world from 2002 to
2005.34 We believe all these factors make allopurinol the leading
culprit for DRESS/DIHS in Taiwan, and further result in a high renal
Figure 1 Clinical presentations of DRESS/DIHS. (A) The skin rash of DRESS usually begins as a nonspeciﬁc morbilliform eruption, which is indistinguishable from other less severe
drug reactions, but it can then progress to (B) a generalized inﬁltrated form or even to exfoliative dermatitis (erythroderma). (C) Typical skin lesions for DRESS are facial edema, (D)
conﬂuent and inﬁltrated plaques, (E) purpuric change, and (F) psoriasiform desquamation as a late stage manifestation. (G) Pin-head sized pustules and (H) atypical target lesions
may also be observed. (I) Mucosal regions can be involved in DRESS/DIHS but are usually mild as cheilitis.
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B virus infection (HBV) is high in Taiwan,35 the hepatic involvement
rate in Taiwan DRESS patients did not absolutely exceed that of
other countries. Besides, we found that DRESS/DIHS patients with
HBV or HCV infection did not tend to have hepatic involvement.15
This indicates that chronic HBV or HCV infection may not be a
risk factor for liver involvement. Fortunately, most patients recov-
ered from hepatic injury spontaneously, and death from hepatic
failure is seldom reported in Taiwan.Diagnostic criteria and differential diagnosis
Because of the diverse cutaneous presentation and variable sys-
temic involvement, diagnosing DRESS/DIHS is often challenging. In
fact, even within the past decade, the existence of this “syndrome”
was still being debated. However, discussion and worldwide
research efforts have helped identify additional characteristics to
improve diagnosis. Most experts agree that DRESS/DIHS has some
special features, including delayed onset and prolonged courses,
Figure 2 Pathologic features of DRESS include (A) epidermal spongiosis, (B) some dyskeratotic cells, interface dermatitis with either a vacuolar or lichenoid pattern indicating (C)
basal cell degeneration, and (D) prominent endothelium, possibly with red blood cell extravasation. (E) Eosinophils and dermal edema may be present. (F) Diffuse or superﬁcial
perivascular lymphocytic inﬁltration is frequently observed, which may be accompanied by endothelial damage and, in rare cases, by red blood cell extravasation presenting as
lymphocytic vasculitis.
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tivation. Better isolation and clariﬁcation of this hypersensitivity
syndrome also helps physicians manage these patients and predict
their clinical course and prognosis. Prior to making the diagnosis of
DRESS/DIHS, clinicians should always rule out other conditions,
especially infection or autoimmune diseases. In order to establish
the correct diagnosis, patients’ symptoms, along with many
asymptomatic signs, should be carefully surveyed.
Diagnostic criteria
Although there is still no universal consensus about the deﬁnition
of DRESS/DIHS, two diagnostic criteria are mainly adopted. The
international Registry of Severe Cutaneous Adverse Reactions
(RegiSCAR) group has suggested a series of inclusion criteria for
suspicious DRESS cases, in which hospitalized patients with a re-
action suspected to be drug related must have at least three of the
following systemic features: acute skin rash; fever above 38 C;
enlarged lymph nodes; internal organ involvement; and hemato-
logical abnormalities, including lymphocytosis or lymphocytope-
nia, eosinophilia, and thrombocytopenia.36 Furthermore, a scoringTable 1 Comparison of clinical features of drug reaction with eosinophilia and systemic
Clinical features Peyrière et al/ France18 Tohyama et al/ Japan21
Top three common
culprit drugs
Aromatic anticonvulsants,
abacavir, nevirapine
Aromatic anticonvulsants,
allopurinol, mexiletine
Fevera 69 90
Skin eruption Morbilliform exanthem Morbilliform exanthem
Lymphadenopathya 18 54
Eosinophiliaa 57 57
Atypical lymphocytesa 7 75
Hepatic involvementa 52 34
Renal involvementa 10 NA
Mortalitya 10e40 5
Data are presented as %.
EM ¼ erythema multiforme; NA ¼ not available.
a Incidence.system should be applied to diagnose an included case as DRESS,
depending on individual ﬁnal scores (Table 2). The strength of the
RegiSCAR criteria lies in selecting patients with a varied phenotype
and making an attempt to exclude other conditions that mimic
DRESS. Disadvantages include the need for hospitalization and a
lengthy process involving many laboratory tests that are not always
readily available. Some cases might be falsely validated as noncases
because of inadequate information. Application of these criteria
may be limited in a hospital-based setting or used only in expert
meetings.37 Moreover, people who are not familiar with criteria in
the RegiSCAR DRESS scoring system may overestimate the value
and misclassify no/possible cases to probable/deﬁnite cases.
Therefore, detailed information about how to apply the RegiSCAR
DRESS scoring system is provided in Table 2.
By contrast, the Japanese consensus group established another
set of criteria, with the inclusion of HHV-6 reactivation as a diag-
nostic criterion for DIHS (Table 3).38 If all criteria are present,
especially evidence of HHV-6 reactivation, the diagnosis of typical
DIHS is made; otherwise, atypical DIHS is diagnosed when the ﬁrst
ﬁve criteria are present. Compared to the RegiSCAR criteria, the
Japanese criteria are more easily applied by general physicians orsymptoms in different studies.
Chen et al/ Taiwan15 Walsh et al/ UK33
Allopurinol, aromatic
anticonvulsants, dapsone
Aromatic anticonvulsants, minocycline,
sulfasalazine
87 100
Morbilliform exanthem, indurated
papules and plaques
Urticated papules, morbilliform
exanthem, EM-like lesions
31 88
52 93
63 NA
80 100
40 7
10 11
Table 2 Scoring system of RegiSCAR for diagnosing drug reaction with eosinophilia and systemic symptoms (DRESS).
Assessment/ Score 1 0 1 Comment
Fever  38.5C No/U Yes Acute episodes
Enlarged lymph nodes No/U Yes >1 cm, 2 different areas (right side plus left side is not adequate)
Eosinophilia
Eosinophils  0.7  109/L or
10% if leukocyte < 4.0  109/L
No/U Yes Score 2 for extreme eosinophilia
 Eosinophils  1.5  109/L or
 20% if leukocyte < 4.0  109/L
Atypical lymphocytes No/U Yes
Skin rash Onset < 21 days prior to hospitalization
Extent >50% body surface area No/U Yes
Rash suggesting DRESS No U Yes 2 symptoms: purpuric changes (other than legs), facial edema, inﬁltration,
psoriasiform desquamation
Biopsy suggesting DRESS No Yes/U Score e1 if results ﬁt any other speciﬁc dermatopathologic diagnosis
Organ involvement Excluding other causes, score maximum of 2
Liver: any 1 criterion No/U Yes  ALT > 2  UNL, twice on successive dates
 D-bil > 2  UNL, twice on successive dates
 AST, T-bil, ALP all >2  UNL, once
Kidney: any 1 criterion No/U Yes  Creatinine > 1.5  patient’s baseline, twice on successive dates
 Proteinuria > 1 g/day, hematuria, decreased creatinine clearance or decreased GFR
Lung: any 1 criterion No/U Yes  Evidence of interstitial lung (CT, x-ray)
 Abnormal bronchoalveolar lavage ﬂuid or biopsy specimen
 Abnormal blood gases
Muscle/Heart: any 1 criterion No/U Yes  Raised serum CPK > 2  UNL
 Raised isoenzyme fractions: CPK-MM (skeletal muscle), CPK-MB (heart muscle)
 Raised troponin T (>0.01 mg/L)
 Abnormal imagings, including chest x-ray, echocardiogram, ECG, EMG, CT, or MRI
Pancreas No/U Yes Amylase and/or lipase > 2  UNL
Other organs No/U Yes Spleen, thyroid gland, central nervous system, gastrointestinal tract
Rash resolution  15 days No/U Yes
Excluding other causes No/U Yes Score 1 if 3 tests are performed and negative
Hepatitis A, B, C At least 2 tests are negative and 1 U: negative
Mycoplasma/chlamydia At least 1 test is negative and 1 U: negative
Antinuclear antibody
Blood culture Sampling within 3 days of index date
Final Score
Final scores: <2: excluded; 2e3: possible; 4e5: probable; > 5: deﬁnite. EBV/CMV and HHV6/7 are also recorded; results, however, do not inﬂuence the score.
ALP ¼ alkaline phosphatase; ALT ¼ alanine transaminase; AST ¼ aspartate transaminase; CMV ¼ cytomegalovirus; CPK ¼ creatine phosphokinase; CPK-MB ¼ creatine
phosphokinase-muscle/brain type; CPK-MM ¼ creatine phosphokinase-muscle type; CT ¼ computed tomography; D-bil ¼ direct bilirubin; DRESS ¼ drug reaction with
eosinophilia and systemic symptoms; EBV ¼ EpsteineBarr virus; ECG ¼ electrocardiogram; EMG ¼ electromyogram; GFR ¼ glomerular ﬁltration rate; HHV ¼ human
herpesvirus; MRI ¼ magnetic resonance image; T-bil ¼ total bilirubin; U ¼ unknown; UNL ¼ upper normal limit.
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oratory tests are easily available, and those tests need not be
repeated. However, some probable cases may not fulﬁll the diag-
nostic criteria set by the Japanese consensus group because not all
well-known symptoms or signs will be present in all patients. In
addition, the list of drugs associated with such hypersensitivityTable 3 Diagnostic criteria for drug-induced hypersensitivity syndrome (DIHS)
established by the Japanese group.38,a
1. Maculopapular rash developing > 3 weeks after starting with a limited
number of drugsb
2. Prolonged clinical symptoms 2 weeks after discontinuation of the causative
drug
3. Fever > 38C
4. Liver abnormalities (alanine aminotransferase > 100 U/L)c
5. Leukocyte abnormalities (at least one present)
a. Leukocytosis (>11  109/L)
b. Atypical lymphocytosis (>5%)
c. Eosinophilia (>1.5  109/L)
6. Lymphadenopathy
7. Human herpesvirus 6 reactivation
Note: From “The diagnosis of a DRESS syndrome has been sufﬁciently established on
the basis of typical clinical features and viral reactivations,” by T. Shiohara, M. Iijima,
Z. Ikezawa, and K. Hashimoto, 2007, Br J Dermatol, 156, p.1083e1084. Copyright
2007, John Wiley and Sons. Adapted with permission.
a The diagnosis is conﬁrmed by the presence of all seven criteria (typical DIHS) or
the presence of ﬁve criteria (1e5, atypical DIHS)
b Limited number of drugs for the majority of cases in Japan includes the
following eight: carbamazepine, phenytoin, phenobarbital, zonisamide, mexiletine,
dapsone, salazosulfapyridine, and allopurinol
c This can be replaced by other organ involvement, such as renal involvement.reaction is getting longer, not just with limited drugs. Another
important issue is the discrepancy in viewing HHV reactivation
between different study groups. Evidence of HHV-6 reactivation is
included as a critical criterion to diagnosing typical DIHS for the
Japanese consensus, but is not enrolled in the scoring system pro-
posed by RegiSCAR group. This may explain the higher HHV-6
reactivation rate for DRESS/DIHS patients in Japanese studies
(62%),21 compared to that in other studies adopting RegiSCAR
criteria (45%),39 and also may help support our view of taking DIHS
as a more typical DRESS. However, the deﬁnite role of viral reac-
tivation in DRESS/DIHS is still debatable, and it has still not been
conclusively explained whether the reactivation of HHV-6 and
other members of the HHV family are part of the disease itself or
whether they are better interpreted as a complication of this
syndrome.Differential diagnosis
The skin rash seen in DRESS/DIHS may be highly variable and dy-
namic as the disease progresses or ﬂuctuates. When cutaneous
manifestation is the ﬁrst symptom, a diagnosis of maculopapular
exanthem is often presumed. When patients have discernible
pustules or bullous lesions, acute generalized exanthematous
pustulosis (AGEP), SJS/TEN, and generalized bullous ﬁxed drug
eruption (GBFDE) should be considered in the differential diag-
nosis.40 However, the onset of skin eruption is usually delayed, and
neither extensive epidermal necrolysis nor subcorneal pustules are
a prominent feature of DRESS/DIHS,32 except in rare cases
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the development of fever, lymphadenopathy, or atypical lympho-
cytosis, acute viral infection should be considered. Primary human
immunodeﬁciency virus, EpsteineBarr virus (EBV) infection, and
reactivation of HHV-6 can all present as mononucleosis-like illness
with rash and systemic symptoms.16 When the liver is involved,
hepatotropic viruses, such as hepatitis viruses, and even pandemic
inﬂuenza infection should be carefully investigated. Viral serolog-
ical tests usually help but correct timing of sampling or repeating
tests is important to optimize their beneﬁt.
Depending on induration and purpuric changes observed in skin
lesions, cutaneous T-cell lymphoma or other hematological disorders
and systemic vasculitis should be carefully ruled out. In addition,
some DRESS patients may eventually progress to erythroderma,
which makes correct diagnosis more challenging. Vasculitis with
multiple organ involvement can mimic systemic drug hypersensi-
tivity. ChurgeStrauss syndrome should be taken into account, espe-
cially when patients also present with systemic eosinophilia. Other
vasculitic diseases to be differentiated include Wegener’s gran-
ulomatosis, polyarteritis nodosa, and even systemic lupus
erythematosus.
Histopathological tests may help to identify the pattern and size
of involved vessels and a serological examination to establish an
autoimmune proﬁle is also essential when such conditions are
strongly suspected. If patients experience rapid deterioration to
erythroderma, a history of pre-existing skin disorders such as
eczema or psoriasis should be sought. Sézary syndrome or other
lymphoma/leukemia is not easily distinguishable from a drug
eruption. Histologically, atypical lymphocytes with epidermotrop-
ism or aberrant intradermal distribution are characteristic. Other-
wise, immunohistochemical staining and establishing cell clonality
in the blood can aid in the diagnosis for lymphoma/leukemia.16
Diagnostic tools for DRESS/DIHS
Determining the culprit drug for DRESS/DIHS patients is critical but
sometimes difﬁcult. Patients might take several medications just
before or during their adverse drug reactions. An additional factor
that makes it difﬁcult to ﬁnd the true drug causing the reaction is
the characteristic delayed onset of symptoms in DRESS/DIHS.
Although drug provocation testing may serve as the gold standard
to establish the diagnosis of drug hypersensitivity, this is not
appropriate for SCARs patients because of the potential life-
threatening risks. Patch testing and the lymphocyte trans-
formation test are two clinical tests that may beneﬁt these patients.
Patch testing has been widely used for diagnosing type IV or
delayed type hypersensitivity. A drug patch test is performed by
applying a diluted drug in suitable media on the skin, to detect
inﬂammatory effects by drug-speciﬁc T-cells. Although it is a safe
test, several factors are known to affect its sensitivity and speci-
ﬁcity. Prior to when patch testing is ordered for DRESS/DIHS pa-
tients, the physician should evaluate some important factors,
including the drug category to be tested, drug concentration and
vehicle used, and timing of the test after drug hypersensitivity.
Overall positive rates for DRESS patch tests are diverse, ranging
from 32.1% to 64%.42,43 However, some similar results have been
repeatedly veriﬁed. In the case of anticonvulsants, studies reported
to have a 51.5% positive rate; especially for carbamazepine, the
positive rate rose to more than 70%.42e44 Other drugs reported to
produce positive patch tests include b-lactam antibiotics, proton
pump inhibitors, and some non-steroidal anti-inﬂammatory
drugs.42,43 By contrast, patch tests always yield negative results in
allopurinol-induced DRESS/DIHS. In a systemic review of anticon-
vulsant hypersensitivity syndrome, performing patch tests during
or right after hypersensitivity episodes yielded low rates of positiveresults. The optimal time for performing this test is 2e6 months
after the initiation of drug reaction.45
The lymphocyte transformation test (LTT) mainly focuses on
detecting drug-speciﬁc T-cells by measuring the proliferation of T-
cells after encountering the antigens. The speciﬁcity of LTT is
evaluated to be 85%,46 but the sensitivity is also variable and is
related to both the drug and phenotype of clinical reactions.47 For
b-lactam-delayed-type allergy, the sensitivity rate of LTT was re-
ported to be in the range of 60e70%.48 However, well-documented
data are lacking for other drugs tested by LTT. Other limitations of
the LTT include its high laboratory test cost, as well as advanced
techniques that demand experience and careful interpretation for
reliable results. Nevertheless, LTT should be considered in patch-
test-negative patients because overall sensitivity is higher than
other tests detecting delayed type hypersensitivity. The optimal
time to perform LTT is still being debated, but for DRESS patients,
5e8 weeks after acute episodes has been suggested.49Pathogenesis
The precise pathogenesis of DRESS/DIHS is complex and not fully
understood. It is widely considered to be an immunological reac-
tion to a drug or to its metabolites because of the signs, such as skin
eruption, fever, and reappearance of symptoms upon readminis-
tration of the drug. However, exposure to associated drugs does not
seem to be enough to develop DRESS/DIHS. Increasing results of
pharmacogenetic studies are showing that the occurrence of this
syndrome is determined by the combination of susceptible in-
dividuals and exposure to speciﬁc drugs. However, the mechanisms
underlying the ﬂaring of symptoms of DRESS/DIHS cannot be
explained solely by an immunological reaction to drugs. The link
between DRESS/DIHS and HHV-6 reactivation has evoked much
interest in recent years. Some authors consider HHV-6 reactivation
a consequence of immunosuppression, either due to drug hyper-
sensitivity or to immunosuppressive treatment17; others view this
as the early event.39 Recently, gradual dysfunction of regulatory T-
cells was reported and was speculated to be associated with
increasing risks of developing autoimmune diseases.50Immunological hypersensitivity reaction
DRESS/DIHS only occurs in a relatively small proportion of patients
and thus is an idiosyncratic hypersensitivity reaction. This syn-
drome is classiﬁed as type IV or delayed type hypersensitivity
because of the need for an incubation period for sensitization.
Activated T-cells seem to play a central role in such hypersensi-
tivity. Some have further claimed that DRESS/DIHS has a dominant
type IVb reaction, which corresponds to the Th2-type immune
response and eosinophil activation.51 Studies have demonstrated
the existence of drug-speciﬁc T-cells in patients with drug hyper-
sensitivity and expansion of these T-cells when encountering spe-
ciﬁc antigens.52 However, their effector roles in DRESS/DIHS are still
elusive. Drugs associated with these reactions may covalently bind
protein or DNA to form hapten-carrier complexes (hapten theory)
or may directly interact with immune receptors on T-cells (p-i
concept) to stimulate the immune cells.53 The interaction between
human leukocyte antigen (HLA), drugs, and T-cell receptors (TCR) is
pivotal to such a T-cell-mediated response. When a drug or
metabolite interacts with a particular HLA, and if drug presentation
to naïve T cells via the TCR stimulates their activation, immune
responses are initiated. Individuals possessing speciﬁc HLA are
predisposed to developing DRESS/DIHS after sensitization by
particular drugs; however, these allelic markers are possibly
necessary but not sufﬁcient to evoke such allergic reactions
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predictive values.54
Scientists ﬁrst found the correlation between HLA and drugs
early in the 21st century. In published data, abacavir-hypersensitive
patients carried the allele HLA-B*5701 more frequently than
abacavir-tolerant patients did (odds ratio: 117; 95% conﬁdence in-
terval 29-481).55 Further studies have demonstrated this correla-
tion in Caucasian and Hispanic patients,56 but not in African and
Asian populations.57 An international randomized pharmacoge-
netic clinical trial proved that avoidance of abacavir use in patients
with allele HLA-B*5701 reduced the incidence of this hypersensi-
tivity syndrome, which was initially seen in 5% of patients receiving
this drug during the ﬁrst weeks of treatment.58 Recently, the
mechanism of T-cell activation by abacavir was explained. Un-
modiﬁed abacavir binds noncovalently to antigen-binding cleft of
HLA-B*5701 and subsequently changes its shape and chemistry,
along with changes to the peptide repertoire of HLA-B*5701. This
repertoire change alters the “immunological self”, after which
loading of novel self-peptides into altered HLA may drive T-cell
immune responses.59,60 This ﬁnding may also partially explain the
occasional occurrence of drug-induced autoimmunity.60 Another
well-known association is HLA-B*5801 and allopurinol-induced
severe drug hypersensitivity reactions. This correlation was ﬁrst
reported in a case-controlled study of a Han-Chinese population.
One-hundred percent of patients diagnosed with allopurinol-
induced SJS/TEN and DRESS/DIHS carried the allele HLA-B*5801,
compared to only 15% in allopurinol-tolerant controls and 20% in
healthy controls.61 Similar strong associations were also demon-
strated in other Southeast Asian populations,62 Japanese pop-
ulations,63 and also European patients64; this was most marked in
allopurinol-induced SJS/TEN. Although the mechanism of interac-
tion between speciﬁc drugs and HLA variants is still not totally
understood, in many countries screening for these alleles is rec-
ommended prior to initiating therapy with these drugs. SCAR
occurrence may be partially preventable in the future.
Viral reactivation
The association between this drug eruption and HHV was ﬁrst re-
ported in a patient with phenobarbital-induced hypersensitivity
syndrome.65 In that study, the authors reported that the antibody
titer of HHV-6 rose during the 2nde4th week after the initiation of
symptoms and this episode of viral infection was claimed to be
related to the fulminant hemophagocytic syndrome developing in
that patient. Since then, continual evidence supports that viral
reactivation might be a unique feature in such drug reaction and
typical DIHS was proposed to imply its association with viral
reactivation.38
Recently, reactivation of other types of herpesviruses was also
discovered through different laboratory modalities; however, the
mechanism for sequential viral reactivation and their pathogenetic
roles in DRESS/DIHS are still unclear. Decreased B-lymphocyte
numbers and total immunoglobulin levels were reported in a com-
parison of patients with DRESS/DIHS and patients with SJS/TEN.66 In
addition, reduction of plasmacytoid dendritic cells (pDC) in the pe-
ripheral circulation was noted, and the authors speculated that this
depressed the antiviral activity in DRESS/DIHS patients because
pDCs induce B cell maturation to produce immunoglobulin.67
The role antiviral T-cells play in DRESS/DIHS is still being
debated. It has been proposed that T-cells speciﬁc to drugs and
viruses may have signiﬁcant cross-reactivity in these patients, so
the clinical symptoms during acute episodes and after drug with-
drawal are partially induced by antiviral T-cells, which are stimu-
lated by bystander activation.17 Another scenario proposes that
antiviral CD8þ T-cells possessing cross-reactivity to drugs play acentral role in initiating this drug hypersensitivity reaction when
the drugs and speciﬁc HLA alleles accidentally activate viral speciﬁc
T-cells.68 Other researchers have demonstrated EBV replication in
patients’ EBV-transformed B lymphocytes after triggering by culprit
drugs. These researchers claimed that symptoms of DRESS are
mediated by activated CD8þ T-cells whose targets in fact are her-
pesviruses.39 However, more evidence is needed to clarify the
interaction between drugs, HHV, and host immune responses in
DRESS/DIHS patients.
Regulatory T-cells
Recently, the roles of regulatory T-cells (Treg) have been studied in
DRESS/DIHS patients, and their dynamic changes applied to explain
some of the mysterious problems of this drug hypersensitivity re-
action. It was observed that Treg cells expanded during acute stages
but gradually lost their function during resolution phases of DRESS/
DIHS.50 This led to the theory that expanded Treg cells with full
capacities suppress activation of effector T-cells. This is reﬂected as
a delayed onset of manifestations of DRESS/DIHS but also para-
doxically facilitates viral reactivation. Exhausted Treg cells become
dysfunctional, which may partially explain why patients with
DRESS/DIHS have an increased risk of developing autoimmune
diseases in the future.68
Treatment and disease outcome
The only consensus about DRESS/DIHS patient treatment is to
withdraw the offending drugs as soon as possible, along with
providing adequate supportive care. Otherwise, it is still inconclu-
sive what treatment beneﬁts DRESS/DIHS patients. Empirical use of
antibiotics or anti-inﬂammatory medications should be avoided to
prevent confusion between true deterioration due to newly
administered drugs or paradoxical deterioration of clinical symp-
toms after withdrawal of causative drugs.
Topical corticosteroids can be used to relieve cutaneous symp-
toms but the risk of superﬁcial infection should always be kept in
mind. Systemic corticosteroids are the current mainstay of treat-
ment. A recommended starting dose is 1.0e1.5 mg/kg/day of
prednisone or an equivalent drug. This dosage should be slowly
tapered over 6e8 weeks to avoid a ﬂare-up of symptoms.17 How-
ever, studies focusing on indications and timing of administration
and the inﬂuence of these factors on long-term outcomes for
DRESS/DIHS patients are lacking. Because some patients may
completely recover without the need for systemic corticosteroids, it
might be unnecessary to give systemic corticosteroids immediately
to all patients suspected of having DRESS/DIHS.69
Other alternatives include intravenous immunoglobulin, plas-
mapheresis, or immunosuppressants; however, reports in the
literature have shown variable outcomes and inconclusive
results.70,71
The estimated mortality from DRESS/DIHS is 10e40%, accord-
ing to different studies (Table 1), and the causes for death include
hepatic necrosis, shock, pulmonary hemorrhage, or other vital
organ decompensation.15,33 Years after the acute stage, patients
may have long-term sequelae, comprising newly developed
autoimmune diseases and permanent visceral organ failure. In our
previous study, the overall cumulative incidence of long-term
sequelae for DRESS/DIHS patients was 11.5%. Autoimmune thy-
roid diseases and renal failure requiring long-term hemodialysis
were the most frequent sequelae for young patients and the
elderly, respectively.72 Variable autoimmune diseases were re-
ported in the literature, and there were occasional reports of in-
dividual patients developing more than one particular disease,
either simultaneously or sequentially.22,73 The pathomechanism
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possibly involves repeated stimulation of T-cells with autoreactive
potentials by sequential viral reactivation and dysfunction of
regulatory T cells at resolution stages.74 However, autoimmune
diseases after DRESS/DIHS are variable, and they may involve both
autoantibody production (for example, autoimmune thyroid dis-
eases or systemic lupus erythematosus) and cell-mediated
mechanisms (for example, alopecia areata or sclerodermoid le-
sions). These are indications that immune regulation imbalance is
multidimensional rather than having a single clear pathogenic
process. Physicians should be aware of autoimmune generation in
patients after DRESS/DIHS and cautiously follow up symptoms
and laboratory tests for early recognition. For elderly patients,
physicians should keep in mind that vital organ failure may lead to
death, which can occur either at the acute stage of the disease or
during the resolution stage of disease.72
Conclusion
DRESS/DIHS is a severe adverse drug reaction with unique clinical
features and complex pathomechanisms. Early recognition, with-
drawal of possible causative drugs, and adequate supportive care
are mainstays of improving patient prognosis and reduce morbid-
ities/mortality. Most patients suffering from DRESS/DIHS recover
completely, but some may develop long-term sequelae, especially
autoimmune diseases and permanent end-organ failure. Patient
education and follow-up are necessary, and the search should
continue for therapies that can reduce the risk of sequelae.
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